Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1978 1
1994 1
1997 2
1998 2
1999 2
2000 6
2001 9
2002 10
2003 19
2004 11
2005 16
2006 25
2007 20
2008 28
2009 21
2010 14
2011 24
2012 25
2013 25
2014 28
2015 31
2016 39
2017 25
2018 35
2019 24
2020 42
2021 27
2022 13
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

483 results
Results by year
Filters applied: . Clear all
Page 1
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. Among authors: steensma dp. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.
Bone marrow niches in haematological malignancies.
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Méndez-Ferrer S, et al. Among authors: steensma dp. Nat Rev Cancer. 2020 May;20(5):285-298. doi: 10.1038/s41568-020-0245-2. Epub 2020 Feb 28. Nat Rev Cancer. 2020. PMID: 32112045 Free PMC article. Review.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres MA, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase D, Tüchler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg E, Cazzola M. Malcovati L, et al. Among authors: steensma dp. Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850. Blood. 2020. PMID: 32347921 Free PMC article. Review.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Lindsley RC, et al. Among authors: steensma dp. Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30. Blood. 2015. PMID: 25550361 Free PMC article.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: steensma dp. Blood. 2020 Aug 6;136(6):674-683. doi: 10.1182/blood.2019004143. Blood. 2020. PMID: 32285126 Free PMC article. Clinical Trial.
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Nazha A, et al. Among authors: steensma dp. J Clin Oncol. 2021 Nov 20;39(33):3737-3746. doi: 10.1200/JCO.20.02810. Epub 2021 Aug 18. J Clin Oncol. 2021. PMID: 34406850 Free PMC article.
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Jabbour E, et al. Among authors: steensma dp. Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3. Blood. 2017. PMID: 28774880 Free PMC article. Clinical Trial.
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias.
Raundhal M, Ghosh S, Myers SA, Cuoco MS, Singer M, Carr SA, Waikar SS, Bonventre JV, Ritz J, Stone RM, Steensma DP, Regev A, Glimcher LH. Raundhal M, et al. Among authors: steensma dp. Nat Immunol. 2021 Apr;22(4):520-529. doi: 10.1038/s41590-021-00895-4. Epub 2021 Mar 22. Nat Immunol. 2021. PMID: 33753942 Free PMC article.
483 results